Pemazyre

Active Ingredient(s): Pemigatinib
FDA Approved: * April 17, 2020
Pharm Company: * INCYTE CORP
Category: Cancer

* This drug may consist of multiple approval dates, manufacturers, or distributors. If applicable, they would be listed below under "NDC Database Records".



Pemazyre Overview

Pemigatinib (INN),[1] sold under the brand name Pemazyre, is a medication for the treatment of adults with previously treated, unresectable locally advanced or metastatic bile duct cancer (cholangiocarcinoma) with a fibroblast growth factor receptor 2 (FGFR2) fusion or other rearrangement as detected by an FDA-approved test.[2][3] Pemigatinib works by blocking FGFR2 in tumor cells to prevent them from growing and spreading.[2] P...

Read more Pemazyre Details
Details May Include Instructions, Side Effects, Interactions, Etc. Drug monograph is from Wikipedia. All text is available under the terms of the GFDL (GNU Free Documentation License). Source: en.wikipedia.org/wiki/Pemigatinib

Recent Pemazyre Forums:

Be the first to start a discussion about this drug.

Possible Dosages for this and Related Drugs:

Pemigatinib
  • Tablet: 13.5mg, 4.5mg, 9mg
Note: Above list includes dosages for all drugs with the same combination of active ingredients.

NDC Database Records for Pemazyre: (3 results)

Sorted by National Drug Code
  • 50881-026 Pemazyre 4.5 mg Oral Tablet by Incyte Corporation
  • 50881-027 Pemazyre 9 mg Oral Tablet by Incyte Corporation
  • 50881-028 Pemazyre 13.5 mg Oral Tablet by Incyte Corporation

Other drugs which contain Pemigatinib or a similar ingredient: (1 result)




Note: All times displayed are GMT - 7.

This information has been independently compiled and is for informational purposes only. It is not intended to be a substitute for medical advice from a qualified healthcare professional; nor is it intended to diagnose, treat, cure or prevent any disease. For more details please see the Medical Disclaimer. This page was last updated on 23 November 2020.

We are committed to your privacy.

Copyright © 2005-2020 All Rights Reserved. MedsChat® is a registered trademark of Limelight Innovations L.L.C. 9888 W Belleview Ave #5000, Denver, CO, 80123, USA